Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy

BMC Cancer

Research Article

Yao-Tsung Yeh¹  Chee-Yin Chai²  Sheau-Fang Yang³  Fu Ou-Yang⁴  Ming-Feng Hou⁴  Fang-Ming Chen⁵  Yang-Chang Wu⁶ 

[1] Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, No.151, Jinxue Rd, Daliao Dist, 831, Kaohsiung, R O C, Taiwan;Department of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Shiquan 1st Rd, Sanmin Dist, 807, Kaohsiung, R O C, Taiwan;Department of Pathology, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, 801, Kaohsiung, R O C, Taiwan;Department of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Shiquan 1st Rd, Sanmin Dist, 807, Kaohsiung, R O C, Taiwan;Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, 801, Kaohsiung, R O C, Taiwan;Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd, Sanmin Dist, 807, Kaohsiung, R O C, Taiwan;Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, 801, Kaohsiung, R O C, Taiwan;Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd, Sanmin Dist, 807, Kaohsiung, R O C, Taiwan;Department of Laboratory, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, 801, Kaohsiung, R O C, Taiwan;School of Pharmacy, College of Pharmacy, China Medical University, No. 91, Hsueh-Shih Road, 40402, Taichung, R O C, Taiwan;Chinese Medicine Research and Development Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, R O C, Taiwan;

关键词: Breast cancer;    Protein inhibitor of activated STAT3;    Estrogen receptor;    Cyclin D1;    Tamoxifen;   

DOI  :  10.1186/s12885-016-2063-1

 received in 2015-06-08, accepted in 2016-01-10,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundDeregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated STAT3 (PIAS3), may contribute to cancer development.MethodsThe expression of total PIAS3 was determined in 100 paired cancerous and non-cancerous breast tissues by immunoblotting and was statistically analyzed along with the clinicopathological characteristics and overall survival of the patients. XTT, immunoblotting, and chromatin immunoprecipitation (Chip) were used to examine the biological effect of PIAS3 in breast cancer cells.ResultsHormone therapy failed to improve the overall survival in patients presenting with increased PIAS3 expression. Ectopic PIAS3 overexpression increased the proliferation and expression of cyclin D1 in estrogen receptor (ER)-positive MCF-7 and T47D cells, but decreased those in ER-negative MDA-MB-231 and SKBR3 cells. Furthermore, PIAS3 overexpression attenuated cytotoxicity of tamoxifen and increased proliferation and cyclin D1 expression in MCF-7 cells. PIAS3 also decreased the binding of itself on the cyclin D1 promoter and this decreased binding was not affected by tamoxifen.ConclusionPIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to those breast cancer patients receiving hormone therapy

【 授权许可】

CC BY   
© Yang et al. 2016